Cardio Diagnostics Holdings, INC

Cardio Diagnostics Holdings, Inc. is holding an investor conference call to discuss corporate updates, recent clinical data, reimbursement progress, and strategic priorities for its precision cardiovascular medicine platform.

Cardio Diagnostics Holdings, Inc. stockholders approved the election of seven directors, a significant share issuance proposal, and the ratification of its independent auditor at the annual meeting.

Cardio Diagnostics Holdings, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, securing its continued listing on The Nasdaq Stock Market.

Cardio Diagnostics Holdings, Inc. implemented a 1-for-30 reverse stock split, effective May 13, 2025, to meet Nasdaq's minimum bid price requirement.

Cardio Diagnostics Holdings Inc. is leveraging epigenetics and artificial intelligence to revolutionize cardiovascular medicine with a suite of diagnostic and risk assessment tools.

Cardio Diagnostics Holdings, Inc. has received a second extension from Nasdaq to regain compliance with the minimum bid price requirement, now until June 2, 2025.

Cardio Diagnostics Holdings, Inc. reported a significant revenue decrease and continued net losses for Q3 2025, alongside an identified material weakness in internal controls.

Cardio Diagnostics Holdings, Inc. reported a significant revenue decrease for the six months ended June 30, 2025, alongside a reduced net loss primarily due to lower stock compensation expenses.

Cardio Diagnostics Holdings, Inc. reported a net loss of $1.635 million on revenue of $940 for the quarter ended March 31, 2025, as the company continues to navigate a strategic shift in its commercialization efforts.

Cardio Diagnostics Holdings reported a net loss of $1.4 million for the third quarter of 2024, alongside increased revenue and ongoing efforts to navigate regulatory changes and financial constraints.

Cardio Diagnostics Holdings reported a net loss of $1.29 million for the second quarter of 2024, alongside a slight increase in revenue and ongoing efforts to navigate regulatory changes.

Cardio Diagnostics Holdings, Inc. reported a net loss of $4.16 million for the first quarter of 2024, with revenue of $15,928 and increased operating expenses.

Cardio Diagnostics Holdings, Inc. reported a reduced net loss in 2025 compared to 2024, despite a decline in revenue, as it continues to focus on commercializing its AI-driven cardiovascular diagnostic tests and expanding market reach.

Cardio Diagnostics Holdings, Inc. reports a slight increase in revenue for 2024 while navigating evolving FDA regulations for laboratory developed tests.

Cardio Diagnostics Holdings, Inc. outlines its capital stock, warrants, and regulatory environment in its annual 10-K filing, highlighting its focus on cardiovascular disease diagnostics.

Peter K. Fung, a Director at Cardio Diagnostics Holdings, Inc., acquired stock options on June 30, 2026, as detailed in a Form 4 filing.

Cardio Diagnostics Holdings, Inc. Director Wendy J. Betts reported a transaction involving the acquisition of stock options and subsequent exercise, impacting her beneficial ownership.

Cardio Diagnostics Holdings, Inc. Director James Intrater acquired stock options, indicating a potential future investment in the company.

Paul Frederick Burton, a Director at Cardio Diagnostics Holdings, Inc., reported the acquisition of stock options and subsequent exercise, increasing his beneficial ownership.

Director Peter K. Fung acquired 3,205 stock options in Cardio Diagnostics Holdings, Inc. as part of a routine equity grant.

Director Wendy J. Betts was granted 3,205 stock options in Cardio Diagnostics Holdings, Inc. as part of a routine equity compensation.

Cardio Diagnostics Holdings, Inc. filed definitive additional materials related to a proxy statement with the SEC.

Cardio Diagnostics Holdings, Inc. is holding its annual meeting on October 15, 2025, seeking stockholder approval for director elections, a significant future share issuance to raise capital, and auditor ratification.

Cardio Diagnostics Holdings, Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Cardio Diagnostics Holdings is holding its annual meeting to vote on key proposals including a reverse stock split, future share issuance, director elections, and auditor ratification.

Cardio Diagnostics Holdings has filed a registration statement for the resale of over 1.2 million shares of common stock by selling stockholders, amidst evolving FDA regulations for laboratory developed tests.